A new tool linking human cytomegalovirus drug resistance mutations to resistance phenotypes

Antiviral Research

Volumn 85, Issue 2, 2010, Pages 318-327

  Chevillotte, Meike ^a   von Einem, Jens ^a   Meier, Benjamin M ^b   Lin, Feng Mao ^c   Kestler, Hans A ^a,b   Mertens, Thomas ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

Author keywords

CDV; Clinical outcome; FOS; GCV; Genotype; HCMV; UL54; UL97

Indexed keywords

ANTIVIRUS AGENT; CIDOFOVIR; DNA POLYMERASE; FOSCARNET; GANCICLOVIR; PROTEIN KINASE; UL54 PROTEIN; UL97 PROTEIN; UNCLASSIFIED DRUG; VALGANCICLOVIR;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; CYTOMEGALOVIRUS INFECTION; DRUG MECHANISM; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN CYTOMEGALOVIRUS; INFECTION PREVENTION; INFECTION RISK; MUTATIONAL ANALYSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SEARCH ENGINE; SEQUENCE DATABASE; SYSTEMIC THERAPY; VIRUS CHARACTERIZATION; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS STRAIN;

AMINO ACID SUBSTITUTION; CYTOMEGALOVIRUS; DATABASES, FACTUAL; DATABASES, GENETIC; DATABASES, NUCLEIC ACID; DNA, VIRAL; DRUG RESISTANCE, VIRAL; GENOTYPE; HUMANS; INTERNET; MUTATION, MISSENSE; PHENOTYPE; VIRAL PROTEINS;

HUMAN HERPESVIRUS 5;

EID: 74649087302     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2009.10.004     Document Type: Review

References (94)

1. Altschul S.F., Gish W., Miller W., Myers E.W., and Lipman D.J. Basic local alignment search tool. J. Mol. Biol. 215 (1990) 403-410
2. Altschul S.F., Madden T.L., Schaffer A.A., Zhang J., Zhang Z., Miller W., and Lipman D.J. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25 (1997) 3389-3402
3. Andrei G., de Clercq E., and Snoeck R. Novel inhibitors of human CMV. Curr. Opin. Investig. Drugs 9 (2008) 132-145
4. Andrei G., de Clercq E., and Snoeck R. Drug targets in cytomegalovirus infection. Infect Disord. Drug Targets 9 (2009) 201-222
5. Baldanti F., Michel D., Simoncini L., Heuschmid M., Zimmermann A., Minisini R., Schaarschmidt P., Schmid T., Gerna G., and Mertens T. Mutations in the UL97 ORF of ganciclovir-resistant clinical cytomegalovirus isolates differentially affect GCV phosphorylation as determined in a recombinant vaccinia virus system. Antiviral Res. 54 (2002) 59-67
6. Baldanti F., Paolucci S., Parisi A., Meroni L., and Gerna G. Emergence of multiple drug resistant human cytomegalovirus variants in 2 patients with human immunodeficiency virus infection unresponsive to highly active antiretroviral therapy. Clin. Infect. Dis. 34 (2002) 1146-1149
7. Baldanti F., Underwood M.R., Stanat S.C., Biron K.K., Chou S.W., Sarasini A., Silini E., and Gerna G. Single amino acids changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J. Virol. 70 (1996) 1390-1395
8. Biron K.K., Fyfe J.A., Stanat S.C., Leslie L.K., Sorrell J.B., Lambe C.U., and Coen D.M. A human cytomegalovirus mutant resistant to the nucleoside analog 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine (BW B759U) induces reduced levels of BW B759U triphosphate. Proc. Natl. Acad. Sci. U.S.A. 83 (1986) 8769-8773
9. Biron K.K., Harvey R.J., Chamberlain S.C., Good S.S., Smith III A.A., Davis M.G., Talarico C.L., Miller W.H., Ferris R., Dornsife R.E., Stanat S.C., Drach J.C., Townsend L.B., and Koszalka G.W. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob. Agents Chemother. 46 (2002) 2365-2372
10. Boeckh M., Fries B., and Nichols W.G. Recent advances in the prevention of CMV infection and disease after hematopoietic stem cell transplantation. Pediatr. Transplant. 8 Suppl 5 (2004) 19-27
11. Boeckh M., and Ljungman P. How we treat CMV in hematopoietic cell transplant recipients. Blood 113 (2009) 5711-5719
12. Boeckh M., Nichols W.G., Papanicolaou G., Rubin R., Wingard J.R., and Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol. Blood Marrow Transplant. 9 (2003) 543-558
13. Boivin G., Gilbert C., Gaudreau A., Greenfield I., Sudlow R., and Roberts N.-A. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. J. Inf. Dis. 184 (2001) 1598-1602
14. Boivin G., Goyette N., Gilbert C., Humar A., and Covington E. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. Transpl. Infect. Dis. 7 (2005) 166-170
15. Boivin G., Goyette N., Gilbert C., Roberts N., Macey K., Paya C., Pescovitz M.-D., Humar A., Dominguez E., Washburn K., Blumberg E., Alexander B., Freeman R., Heaton N., and Covington E. Absence of cytomegalovirus resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid organ transplant recipients. J. Inf. Dis. 189 (2004) 1615-1618
16. Bourgeois C., Sixt N., Bour J.B., and Pothier P. Value of a ligase chain reaction assay for detection of ganciclovir resistance-related mutation 594 in UL97 gene of human cytomegalovirus. J. Virol. Methods 67 (1997) 167-175
17. Chevillotte M., Schubert A., Mertens T., and von Einem J. A fluorescence-based assay for phenotypic characterisation of human cytomegalovirus polymerase mutations regarding drug susceptibility and viral replicative fitness. Antimicrob. Agents Chemother. 53 (2009) 3752-3761
18. Chou S. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev. Med. Virol. 18 (2008) 233-246
19. Chou S. Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. Antimirob. Agents Chemother. 53 (2009) 81-85
20. Chou S., and Marousek G.I. Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. J. Virol. 82 (2008) 246-253
21. Chou S., Marousek G.I., Senters A.E., Davis M.G., and Biron K.K. Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir. J. Virol. 78 (2004) 7124-7130
22. Chou S., Marousek G.I., Van Wechel L.C., Li S., and Weinberg A. Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. Antimicrob. Agents Chemother. 51 (2007) 4160-4162
23. Chou S.W. Antiviral drug resistance in human cytomegalovirus. Transpl. Infect. Dis. 1 (1999) 105-114
24. Chou S.W., Erice A., Jordan M.C., Vercellotti G.M., Michels K.R., Talarico C.L., Stanat S.C., and Biron K.K. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J. Infect. Dis. 171 (1995) 576-583
25. Chou S.W., Guentzel S., Michels K.R., Miner R.C., and Drew W.L. Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J. Infect. Dis. 172 (1995) 239-242
26. Chou S.W., Lurain N.S., Thompson K.D., Miner R.C., and Drew W.L. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J. Infect. Dis. 188 (2003) 32-39
27. Chou S.W., Marousek G., Guentzel S., Follansbee S.E., Poscher M.E., Lalezari J.P., Miner R.C., and Drew W.L. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J. Infect. Dis. 176 (1997) 786-789
28. Chou S.W., Miner R.C., and Drew W.L. A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance. J. Infect. Dis. 182 (2000) 1765-1768
29. Chou S.W., van Wechel L.C., Lichy H.M., and Marousek G. Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene. Antimicrob. Agents Chemother. 49 (2005) 2710-2715
30. Chrisp P., and Clissold S.P. Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 41 (1991) 104-129
31. Cihlar T., and Chen M.S. Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells. Mol. Pharmacol. 50 (1996) 1502-1510
32. Cihlar T., Fuller M.D., and Cherrington J.M. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. J. Virol. 72 (1998) 5927-5936
33. Cihlar T., Fuller M.D., Mulato A.S., and Cherrington J.M. A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. Virology 248 (1998) 382-393
34. Dal Pozzo F., Andrei G., Daelemans D., Winkler M., Piette J., De Clercq E., and Snoeck R. Fluorescence-based antiviral assay for the evaluation of compounds against vaccinia virus, varicella zoster virus and human cytomegalovirus. J. Virol. Methods 151 (2008) 66-73
35. Drew W.L. Ganciclovir resistance: a matter of time and titre. Lancet 356 (2000) 609-610
36. Drew W.L. Laboratory diagnosis of cytomegalovirus infection and disease in immunocompromised patients. Curr. Opin. Infect. Dis. 20 (2007) 408-411
37. Drew W.L., Miner R.C., Marousek G., and Chou S.W. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J. Clin. Virol. 37 (2006) 124-127
38. Ducancelle A., Alain S., Petit F., Sanson Le Pors M.J., and Mazeron M.C. Development and validation of a non-radioactive DNA polymerase assay for studying cytomegalovirus resistance to foscarnet. J. Virol. Methods 141 (2007) 212-215
39. Ducancelle A., Gravisse J., Alain S., Fillet A.M., Petit F., Sanson Le Pors M.J., and Mazeron M.C. Phenotypic characterisation of cytomegalovirus DNA polymerase: a method to study cytomegalovirus isolates resistant to foscarnet. J. Virol. Methods 125 (2005) 145-151
40. Eckle T., Lang P., Prix L., Jahn G., Klingebiel T., Handgretinger R., Selle B., Niethammer D., and Hamprecht K. Rapid development of ganciclovir-resistant cytomegalovirus infection in children after allogeneic stem cell transplantation in the early phase of immune cell recovery. Bone Marrow Transplant. 30 (2002) 433-439
41. Eckle T., Prix L., Jahn G., Klingebiel T., Handgretinger R., Selle B., and Hamprecht K. Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. Blood 96 (2000) 3286-3289
42. Egli A., Binggeli S., Bodaghi S., Dumoulin A., Funk G.A., Khanna N., Leuenberger D., Gosert R., and Hirsch H.H. Cytomegalovirus and polyomavirus BK posttransplant. Nephrol. Dial. Transplant. 22 (2007) viii72-viii82
43. Einsele H., Ehninger G., Hebart H., Wittkowski K.M., Schuler U., Jahn G., Mackes P., Herter M., Klingebiel T., and Loffler J. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 86 (1995) 2815-2820
44. Emery V.C., and Griffiths P.D. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 8039-8044
45. Erice A., Borrell N., Li W., Miller W.J., and Balfour Jr. H. Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus (CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis. J. Infect. Dis. 178 (1998) 531-534
46. Erice A., Gil-Roda C., Pérez J.L., Balfour H.H., Sannerud K.J., Hanson M.N., Boivin G., and Chou S.W. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J. Infect. Dis. 175 (1997) 1087-1092
47. Faizi Khan R., Mori S., Eizuru Y., Kumura Ishii K., and Minamishima Y. Genetic analysis of a ganciclovir-resistant human cytomegalovirus mutant. Antiviral Res. 40 (1998) 95-103
48. Gilbert C., and Boivin G. Human cytomegalovirus resistance to antiviral drugs. Antimicrob. Agents Chemother. 49 (2005) 873-883
49. Gilbert C., and Boivin G. New reporter cell line to evaluate the sequential emergence of multiple human cytomegalovirus mutations during in vitro drug exposure. Antimicrob. Agents Chemother. 49 (2005) 4860-4866
50. Goossens V.J., Wolffs P.F., van L.I., Bruggeman C.A., and Verbon A. CMV DNA levels and CMV gB subtypes in ART-naive HAART-treated patients: a 2-year follow-up study in The Netherlands. AIDS 23 (2009) 1425-1429
51. Hertenstein B., Hampl W., Bunjes D., Wiesneth M., Duncker C., Koszinowski U., Heimpel H., Arnold R., and Mertens T. In vivo/ex vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT. Bone Marrow Transplant. 15 (1995) 387-393
52. Ijichi O., Michel D., Mertens T., Miyata K., and Eizuru Y. GCV resistance due to the mutation A594P in the cytomegalovirus protein UL97 is partially reconstituted by a second mutation at D605E. Antiviral Res. 53 (2002) 135-142
53. Iwasenko J.M., Scott G.M., Rawlinson W.D., Keogh A., Mitchell D., and Chou S. Successful valganciclovir treatment of post-transplant cytomegalovirus infection in the presence of UL97 mutation N597D. J. Med. Virol. 81 (2009) 507-510
54. Jabs D.A., Enger C., and Dunn J.P. Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. J. Infect. Dis. 177 (1998) 770-773
55. Jabs D.A., Enger C., Forman M., and Dunn J.P. Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. Antimicrob. Agents Chemother. 42 (1998) 2240-2244
56. Julin J.E., van Burik J.H., Krivit W., Webb C., Holman C.J., Clark H.B., and Balfour Jr. H.H. Ganciclovir-resistant cytomegalovirus encephalitis in a bone marrow transplant recipient. Transpl. Infect. Dis. 4 (2002) 201-206
57. Kedhar S.R., and Jabs D.A. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Herpes 14 (2007) 66-71
58. Komazin G., Ptak R.G., Emmer B.T., Townsend L.B., and Drach J.C. Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27. J. Virol. 77 (2003) 11499-11506
59. Landry, M.L., Stanat, S., Biron, K., Brambilla, D., Britt, W., Jokela, J., Chou, S., Drew, W.L., Erice, A., Gilliam, B., Lurain, N., Manischewitz, J., Miner, R., Nokta, M., Reichelderfer, P., Spector, S., Weinberg, A., Yen-Lieberman, B., Crumpacker, C., A.C.T.G.C.M.V.R.W.G., 2000. A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates. Antimicrob. Agents Chemother. 44, 688-692.
60. Limaye A.P., Corey L., Koelle D.M., Davis C.L., and Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 356 (2000) 645-649
61. Luganini A., Caposio P., Mondini M., Landolfo S., and Gribaudo G. New cell-based indicator assays for the detection of human cytomegalovirus infection and screening of inhibitors of viral immediate-early 2 protein activity. J. Appl. Microbiol. 105 (2008) 1791-1801
62. Lurain N.S., Thompson K.D., Holmes E.W., and Read S. Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents. J. Virol. 66 (1992) 7146-7152
63. Marfori J., Exner M.M., Marousek G.I., Chou S., and Gilbert C. Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogenic stem cell recipients. J. Clin. Virol. 38 (2007) 120-125
64. Marschall M., Freitag M., Weiler S., Sorg G., and Stamminger T. Recombinant green fluorescent protein-expressing human cytomegalovirus as a tool for screening antiviral agents. Antimicrob. Agents Chemother. 44 (2000) 1588-1597
65. Martin M., Gilbert C., Covington E., and Boivin G. Characterization of human cytomegalovirus (HCMV) UL97 mutations found in a valganciclovir/oral ganciclovir prophylactic trial by use of a bacterial artificial chromosome containing the HCMV genome. J. Infect. Dis. 194 (2006) 579-583
66. Michel D., Lanz K., Michel M., Wasner T., Hauser I., Just M., Hampl W., Mertens T., Prösch S., Cinatl J., and Scholz M. Fast Genotypic Identification and Estimation of Ganciclovir-resistant Cytomegalovirus from Clinical Specimens, New Aspects of CMV-related Immunopathology (2003), Karger, Basel pp. 160-170
67. Michel D., Schaarschmidt P., Wunderlich K., Heuschmid M., Simoncini L., Mühlberger D., Zimmermann A., Pavic I., and Mertens T. Functional regions of the human cytomegalovirus protein pUL97 involved in nuclear localization and phosphorylation of ganciclovir and pUL97 itself. J. Gen. Virol. 79 (1998) 2105-2112
68. Mousavi-Jazi M., Schloss L., Drew W.L., Linde A., Miner R.C., Harmenberg J., Wahren B., and Brytting M. Variations in the cytomegalovirus DNA polymerase and phosphotransferase genes in relation to foscarnet and ganciclovir sensitivity. J. Clin. Virol. 23 (2001) 1-15
69. Müller B., and Kräusslich H.G. Antiviral strategies. Handb. Exp. Pharmacol. 189 (2009) 1-24
70. Nijhuis M., van Maarseveen N.M., and Boucher C.A.B. Antiviral resistance and impact on viral replication capacity: Evolution of viruses under antiviral pressure occurs in three phases. Handb. Exp. Pharmacol. 189 (2009) 299-320
71. Oshima K., Kanda Y., Kako S., sano-Mori Y., Watanabe T., Motokura T., Chiba S., Shiraki K., and Kurokawa M. Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes. J. Med. Virol. 80 (2008) 1769-1775
72. Palella Jr. F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., Aschman D.J., and Holmberg S.D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338 (1998) 853-860
73. Reusser P., Cordonnier C., Einsele H., Engelhard D., Link D., Locasciulli A., and Ljungman P. European survey of herpesvirus resistance to antiviral drugs in bone marrow transplant recipients. Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 17 (1996) 813-817
74. Reusser P., Einsele H., Lee J., Volin L., Rovira M., Engelhard D., Finke J., Cordonnier C., Link H., and Ljungman P. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 99 (2002) 1159-1164
75. Ronaghi M., Uhlén M., and Nyrén P. A sequencing method based on real-time pyrophosphate. Science 281 (1998) 363-365
76. Schnepf N., Boiteau N., Petit F., Alain S., Sanson-Le Pors M.-J., and Mazeron M.C. Rapid determination of antiviral drug susceptibility of human cytomegalovirus by real-time PCR. Antiviral Res. 81 (2009) 64-67
77. Schreiber A., Härter G., Schubert A., Bunjes D., Mertens T., and Michel D. Antiviral treatment of cytomegalovirus infection and resistant strains. Expert Opin. Pharmacother. 10 (2009) 191-209
78. Scott G.M., Weinberg A., Rawlinson W.D., and Chou S.W. Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. Antimicrob. Agents Chemother. 51 (2007) 89-94
79. Sia I.G., and Patel R. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin. Microbiol. Rev. 13 (2000) 83-121
80. Sinzger C., Hahn G., Digel M., Katona R., Sampaio K.L., Messerle M., Hengel H., Koszinowski U., Brune W., and Adler B. Cloning and sequencing of a highly productive, endotheliotropic virus strain derived from human cytomegalovirus TB40/E. J. Gen. Virol. 89 (2008) 359-368
81. Smith I., Cherrington J.M., Jiles R.E., Fuller M.D., and Freeman W.R. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J. Infect. Dis. 176 (1997) 69-77
82. Springer C.L., Chou S.W., Li S., Giller R.H., Quinones R., Shira J.E., and Weinberg A. How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. J. Clin. Microbiol. 43 (2005) 208-213
83. Sullivan V., Talarico C.L., Stanat S.C., Davis M., Coen D.M., and Biron K.K. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 358 (1992) 162-164
84. Sun H.Y., Wagener M.M., and Singh N. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review. Am. J. Transplant. 8 (2008) 2111-2118
85. Tchesnokov E.P., Gilbert C., Boivin G., and Götte M. Role of helix P of the human cytomegalovirus DNA polymerase in resistance and hypersusceptibility to the antiviral drug foscarnet. J. Virol. 80 (2006) 1440-1450
86. ter Meulen C.G., Wetzels J.F.M., and Hilbrands L.B. The influence of mycophenolate mofetil on the incidence and severity of primary cytomegalovirus infections and disease after renal transplantation. Nephrol. Dial. Transplant. 15 (2000) 711-714
87. Tischer B.K., von Einem J., Kaufer B., and Osterrieder N. Two-step Red-mediated recombination for versatile high-efficiency markerless DNA manipulation in Escherichia coli. BioTechniques 40 (2006) 191-197
88. Ueno T., Eizuru Y., Katano H., Kurata T., Sata T., Irie S., and Ogawa-Goto K. Novel real-time monitoring system for human cytomegalovirus-infected cells in vitro that uses a green fluorescent protein-PML-expressing cell line. Antimicrob. Agents Chemother. 50 (2006) 2806-2813
89. Ueno T., and Ogawa-Goto K. Use of a GFP-PML-expressing cell line as a biosensor for human cytomegalovirus infection. Methods Mol. Biol. 515 (2009) 33-44
90. Vigano M., Dengler T., Mattei M.F., Poncelet A., Vanhaecke J., Vermes E., Kleinloog R., Li Y., Gezahegen Y., and Delgado J.F. Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study. Transpl. Infect. Dis (2009)
91. von Müller L., Schliep C., Storck M., Hampl W., Schmid T., Abendroth D., and Mertens T. Severe graft rejection, increased immunosuppression, and active CMV infection in renal transplantation. J. Med. Virol. 78 (2006) 394-399
92. Warming S., Costantino N., Court D., Jenkins N.A., and Copeland N.G. Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res. 33 (2005) e36
93. Weinberg A., Jabs D.A., Chou S.W., Martin B.K., Lurain N.S., Forman M.S., and Crumpacker C.S. Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. J. Infect. Dis. 187 (2003) 777-784
94. Wolf D.G., Yaniv I., Honigman A., Kassis I., Schonfeld T., and Ashkenazi S. Early emergence of ganciclovir-resistant human cytomegalovirus strains in children with primary combined immunodeficiency. J. Infect. Dis. 178 (1998) 535-538